| 05/05 | RemeGen Co., Ltd. Approves Appointment of Chen Yunjin as Independent Non-Executive Dire.. | CI |
| 04/28 | RemeGen Widens Q1 Loss as R&D, Selling Expenses Balloon | MT |
| 04/27 | RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 04/12 | RemeGen Co., Ltd. Announces Executive Changes | CI |
| 04/11 | UBS Upgrades RemeGen to Buy From Neutral, Adjusts Price Target to HK$75.03 From HK$108 | MT |
| 03/31 | RemeGen Lists in Shanghai's STAR Market | MT |
| 03/22 | RemeGen Prices Shanghai IPO to Raise $410 Million | MT |
| 02/20 | RemeGen Turns to Profit in 2021 on Launch of Core Autoimmune, Cancer Drugs; Shares Rise.. | MT |
| 02/20 | RemeGen Co., Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 20.. | CI |
| 01/25 | Remegen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of .. | CI |
| 01/24 | RemeGen Completes Phase 2 Trial of Sjögren's Syndrome Treatment in China | MT |
| 01/24 | RemeGen Co., Ltd. Completes the Phase II Clinical Study for Telitacicept to Treat Patie.. | CI |
| 01/12 | Hong Kong Stocks Jump to Seven-Week High; RemeGen Climbs 9% on Shanghai IPO Approval | MT |
| 01/12 | Chinese Regulator Approves RemeGen's Shanghai IPO Application; Shares Jump 9% | MT |
| 01/05 | Chinese Regulators Grant Conditional Marketing Approval to Remegen's Urothelial Carcino.. | MT |
| 01/05 | RemeGen Co., Ltd. Announces National Medical Products Administration Grants Conditional.. | CI |
| 2021 | RemeGen's Trustee Acquires Shares Under Share Award, Trust Scheme | MT |
| 2021 | RemeGen Buying Filtration Devices From Contract Development Firm | MT |
| 2021 | Chinese Regulators Accept RemeGen's Application for Clinical Trial of Combination Drugs.. | MT |
| 2021 | China Includes Two RemeGen Drugs to New National Reimbursement List | MT |
| 2021 | RemeGen Shareholders to Vote Dec. 20 on Employee Incentive Tied to Shanghai IPO | MT |
| 2021 | RemeGen's Telitacicept and Disitamab Vedotin Enter China's National Reimbursement Drug .. | CI |
| 2021 | RemeGen's January-September Loss Widens on Higher Expenses | MT |
| 2021 | RemeGen Gets STAR Market Listing Approval a Year after Hong Kong Debut | MT |
| 2021 | Certain Domestic Shares of RemeGen Co., Ltd. are subject to a Lock-Up Agreement Ending .. | CI |
| 2021 | RemeGen Files for Shanghai IPO One Year after Hong Kong Debut | MT |
| 2021 | RemeGen Co., Ltd. Provides Earnings Guidance for the Period from January to September 2.. | CI |
| 2021 | Seagen Swings to Q3 Loss as Revenue Drops; Shares Rise After Hours | MT |
| 2021 | Seagen Inc. Enters into License Agreement with RemeGen Co., Ltd | CI |
| 2021 | China's biotech sector comes of age with big licensing deals, global ambitions | RE |
| 2021 | Remegen Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 | CI |
| 2021 | REMEGEN : Completes Phase II Trial of Berger's Disease Treatment in China; Shares Jump 3% | MT |
| 2021 | REMEGEN : Strikes $2.6 Billion Cancer Drug Licensing Deal with Nasdaq-listed Seagen | MT |
| 2021 | Announces Preliminary Result of Telitacicept in the Phase II Study to Treat IGA Nephrop.. | CI |
| 2021 | REMEGEN : Wins Regulatory Nod to Conduct Clinical Trial of Tumor Drug in Australia | MT |
| 2021 | RemeGen Co., Ltd. Receives an Ethical Approval from the Human Research Ethics Committee.. | CI |
| 2021 | REMEGEN : China Accepts RemeGen's New Drug Application for Cancer Medication | MT |
| 2021 | Remegen Co., Ltd. Announces That the National Medical Products Administration Has Accep.. | CI |
| 2021 | REMEGEN : Cancer Drug Secures Breakthrough Therapy Designation in China | MT |
| 2021 | REMEGEN : Shanghai Bourse Accepts RemeGen's IPO Application | MT |
| 2021 | REMEGEN CO., LTD.(SEHK : 9995) added to FTSE All-World Index | CI |
| 2021 | REMEGEN : Drug Granted Marketing Approval | MT |
| 2021 | REMEGEN : Announcement regarding h share full circulation listing approval granted by the .. | PU |
| 2021 | REMEGEN : (1) proposed issue of a shares and listing on the sci-tech board and other ancil.. | PU |
| 2021 | REMEGEN : Notice of the 2021 first class meeting of h shareholders | PU |
| 2021 | REMEGEN : Proxy form for use at the 2021 first class meeting of h shareholders | PU |
| 2021 | REMEGEN : Proxy form for use at the 2021 first class meeting of domestic shareholders and .. | PU |
| 2021 | RemeGen Shareholders to Vote June 1 on Shanghai Listing Proposal | MT |
| 2021 | REMEGEN : Notice of the 2021 first class meeting of domestic shareholders and unlisted for.. | PU |
| 2021 | REMEGEN : Notice of the 2021 second extraordinary general meeting | PU |
| 2021 | REMEGEN : Proxy form for use at the 2021 second extraordinary general meeting | PU |
| 2021 | RemeGen Eyes Secondary Listing in Shanghai | MT |
| 2021 | REMEGEN : Proposed issue of a shares and listing on the sci-tech board and other ancillary.. | PU |
| 2021 | RemeGen Co., Ltd. Announces Board Changes | CI |
| 2021 | Certain Domestic Shares of RemeGen Co., Ltd. are subject to a Lock-Up Agreement Ending .. | CI |
| 2021 | REMEGEN : Buys Research and Development Equipment from MabPlex International for Nearly $3.. | MT |
| 2021 | REMEGEN : Connected transaction in relation to acquisition of assets | PU |
| 2021 | Remegen Co., Ltd. Enters into an Equipment Purchase Contract and A Purchase Contract wi.. | CI |
| 2021 | REMEGEN : Notice of 2020 annual general meeting | PU |
| 2021 | REMEGEN : Clarification announcement relating to the 2020 results announcement | PU |
| 2021 | REMEGEN : Closure of register of members for 2020 annual general meeting and 2021 second e.. | PU |
| 2021 | Remegen Co., Ltd. Announces Change of Principal Place of Business in Hong Kong | CI |
| 2021 | RemeGen Co., Ltd. Announces Earnings Results for the Year Ended December 31, 2020 | CI |
| 2021 | REMEGEN : Inside information announcement - approval by the csrc of the application in res.. | PU |
| 2021 | REMEGEN : Poll results of the 2021 first extraordinary general meeting | PU |
| 2021 | REMEGEN CO., LTD.(SEHK : 9995) added to S&P Global BMI Index | CI |
| 2021 | REMEGEN : Wins Conditional Marketing Nod for Lupus Drug in China | MT |
| 2021 | REMEGEN : Inside information announcement - national medical products administration grant.. | PU |
| 2021 | Remegen Co., Ltd. Announces National Medical Products Administration Granted Conditiona.. | CI |
| 2021 | REMEGEN : Proxy form for use at the 2021 first extraordinary general meeting | PU |
| 2021 | REMEGEN : Notice of 2021 first extraordinary general meeting | PU |
| 2021 | REMEGEN : (1) proposed adoption of the first h share award and trust scheme; (2) proposed .. | PU |
| 2020 | REMEGEN : Shares Surge 13% as Kidney Drug Wins US FDA Nod to Start Phase Two Trial | MT |
| 2020 | REMEGEN : Raises $74 Million More from Exercising Over-Allotment Option on IPO | MT |
| 2020 | REMEGEN : Solid Tumor Drug Wins Clinical Trial Approval in China | MT |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
